

27 May 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Biogen's immunology acquisition; AstraZeneca looks to cement respiratory lead; why US FTC is tough on pharma; the US election's impact on pharma; and how new AI tools are impacting medical affairs.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 24 May 2024, including: [Biogen, Inc.](#)'s immunology acquisition; [AstraZeneca PLC](#) looks to cement respiratory lead; why the US FTC is tough on pharma; the US election's impact on pharma; and how new AI tools are impacting medical affairs.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Biogen Buys Desired Growth In Immunology With \\$1.15bn Hi-Bio Deal](#)" - Scrip, 22 May, 2024.)

(Also see "[AstraZeneca Confident Of Cementing Lead In Respiratory](#)" - Scrip, 17 May, 2024.)

(Also see "[FTC Is Taking A Tougher Stance On Pharma; A Deputy Director Explains Why](#)" - Scrip, 16 May, 2024.)

(Also see "[*The Looming US Election Weighs On The Minds Of Pharma*](#)" - Scrip, 20 May, 2024.)

(Also see "[*'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o*](#)" - Scrip, 21 May, 2024.)

[Click here to explore this interactive content online](#) 